Alkermes, J&J’s Janssen Sue to Block Rival Schizophrenia Drug

Alkermes and J&J’s Janssen unit said Luye Pharma’s proposal for an injectable version of the schizophrenia-treatment drug risperidone infringes a patent for Risperdal Consta, a long-acting injected medication.

• Alkermes and J&J are seeking a court order blocking Luye’s product until the day after the patent’s expiration, and to collect cash compensation if the product is made before then, according to complaint filed July 17 in federal court in Wilmington, Delaware
• Alkermes owns the patent and Janssen holds an exclusive license, complaint says
• Patent’s pediatric exclusivity ends in November 2020: FDA Orange Book
• Risperdal Consta had U.S. sales of $77 million ...